Allena Pharmaceuticals, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Net loss
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Depreciation expense
Non-cash interest expense
Non-cash lease expense
Amortization of premium on investments
Loss on extinguishment of debt
Change in fair value of warrant liability
Loss (gain) on sale of equipment
Changes in assets and liabilities:
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses
Operating lease liabilities
Other liabilities
Net cash used in operating activities

Net cash used in operating activities
Cash flows from investing activities:
Purchases of property and equipment
Purchases of investments
Maturities of investments
Sales of property and equipment
Net cash used in investing activities
Proceeds from the issuance of common stock, net of issuance costs

Cash flows from financing activities:
Proceeds from (payments of issuance costs related to) the issuance of common stock, net of issuance costs
Proceeds from exercise of stock options
Proceeds from issuance of stock through ESPP
Proceeds from loan payable
Repayment of loan payable
Debt issuance costs paid
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Other
Net cash provided by (used in) financing activities

Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Cash paid for interest
Supplemental disclosures:
Cash paid for interest
Initial public offering costs included in accounts payable and accrued expenses
Property and equipment purchases included in accounts payable
Right-of-use assets obtained in exchange of operating lease obligations
Issuance costs included in accounts payable and accrued expenses
Accretion of convertible preferred stock to redemption value

Comments